These stocks reporting next week have a history of beating expectations

Next week’s earnings calendar features 121 S&P 500 companies, with Repligen and HubSpot highlighted as names that have historically beaten expectations and seen shares rise about 3.1% after reporting. Repligen has a $160 target from Redburn, implying about 41% upside, while Bank of America’s $300 target on HubSpot implies roughly 32% upside. Other names screened for positive post-earnings surprise history include Shopify, RingCentral and The Trade Desk.

Analysis

The market is entering a classic post-pivot earnings window where the stocks most likely to gap are not the mega-caps with the cleanest fundamentals, but the names with the most compressed expectations and the highest short-term positioning risk. RGEN and HUBS stand out because both have credible fundamental catalysts, but more importantly because their recent selloffs leave room for a reflexive re-rating if guidance merely confirms that demand is not deteriorating as fast as the market fears. In that setup, the first move is likely driven less by the print itself and more by whether management language reduces the perceived probability of multiple compression continuing into the next quarter.

The second-order beneficiary set is broader than the article suggests. A clean beat from HUBS would likely support the entire high-growth software complex by easing fears that frontier-model efficiency is structurally eroding application-layer pricing power; that matters most for names trading on durability of SMB workflows and retention, not just revenue growth. For RGEN, a positive reaction would reinforce the idea that life-sciences tools can still command premium multiples despite funding-cycle fatigue, which could spill into adjacent bioprocessing and consumables names where investors have been waiting for a signal that end-market normalization is not just a one-off.

The main risk is that these are “good businesses, bad stocks” setups: even strong prints may not lead to sustained upside unless forward commentary restores confidence in 2H visibility. If managements emphasize caution on pipeline conversion, customer budget discipline, or elongated sales cycles, the stocks can give back the initial pop within 1-3 sessions because the market will treat any beat as backward-looking. The broader downside catalyst is not missing consensus; it is issuing guidance that implicitly validates the bear case on growth durability.

The contrarian read is that consensus may be overpricing a clean upside surprise while underpricing the market’s willingness to forgive medium-quality guidance if it comes with credible operating leverage. That creates asymmetric event risk in the options market: the right trade is likely not outright directionality ahead of the prints, but owning convexity where implied volatility still understates the probability of a 6-10% post-earnings move in either direction.

Key Decisions for Investors

• Buy short-dated call spreads in RGEN into the print, targeting a 1-2 week horizon; structure for a 2:1 to 3:1 payoff if the stock re-rates on any raise/beat combination, with defined loss if guidance disappoints.
• Initiate a tactical long HUBS vs short a basket of lower-quality SaaS beta into earnings; if HUBS confirms reacceleration, the pair should outperform on multiple expansion, while limiting sector-wide factor risk.
• Use a post-earnings strength signal to add to RGEN and HUBS only on first-day consolidation, not pre-print; the best risk/reward is often the day after when implied volatility has collapsed and direction is clearer.
• Fade any weak earnings reaction in SHOP or TTD only if the print is fine but guidance is cautious; these names can overshoot on sentiment, so wait for confirmation that the market is extrapolating a transitory miss into a structural slowdown.
• Avoid taking a large directional position in DIS or MCD ahead of the release; these are lower-convexity setups where the upside from a beat is likely capped unless management changes the medium-term margin narrative.